Prospective Registry for Skeletal Metastasis treated with Palliative intent Radiation

The third most common organ to be affected by metastatic disease is bone, which is a frequent manifestation of advanced malignancy. Bone metastases (BM) lead to several morbidities and lower quality of life. Patients with BM are susceptible to high rates (50-70%) of complications such as paraplegia, fractures, and acute or chronic pain. It has been observed that these complications can be reduced by certain bone-modifying agents such as bisphosphonates and Radiotherapy (RT). Research studies have shown that RT substantially decreases complications in symptomatic or high-risk asymptomatic BM disease patients. So in this observational study, we aim to evaluate skeletal-related events (SRE) in both symptomatic and high-risk asymptomatic BM (>50% cortical destruction, > 3 cm maximum diameter, axial cortical involvement of > 3 cm, multi-focal lytic lesion) patients treated with RT. Patients with histologically confirmed malignancy diagnosis with BM and fulfilling inclusion criteria will be screened and invited to participate. Those who give written informed consent will be enrolled in the study. Incidence of SRE will be assessed initially at 6 months. SRE constitutes spinal cord compression, pathological fractures, and /or orthopedic surgery in the irradiated bony region. Pain response and analgesic usage patterns will be evaluated, and post-RT acute and late toxicities will be documented as per Common Toxicities Criteria for Adverse Events (CTCAE) v5.0.